Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Prostatic Neoplasms 16Neoplasms 6Prostate Cancer Metastatic 4Solid Cancer 1Small Cell Lung Carcinoma 1Prostatic Neoplasms, Castration-Resistant 1Neoplasm Metastasis 1Metastatic Castration-resistant Prostate Neoplasms 1Metastatic Castration-resistant Prostate Cancer, MCRPC 1Malignant Solid Tumor - Malignant Nervous System Neoplasm 1Castrate-Resistant Prostate Cancer 1Advanced Solid Tumor 1

Interventions

Injections 24pembrolizumab 13toripalimab 12tislelizumab 9Gemcitabine 7Cisplatin 7Carboplatin 6atezolizumab 5Nivolumab 5Irinotecan 5Pemetrexed 4Oxaliplatin 4Leucovorin 4Fluorouracil 4Docetaxel 4Cetuximab 4trastuzumab deruxtecan 3spartalizumab 3cediranib 3Paclitaxel 3PM 01183 3Capecitabine 3sintilimab 2olaparib 2lenvatinib 2glumetinib 2camrelizumab 2apatinib 2Therapeutics 2Midazolam 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Solid Tumor × cabazitaxel × Clear all
NCT01755390 2012-12-24

A Dose Finding Study of XRP6258 in Patients With Advanced Solid Tumors

Sanofi

Phase 1 Completed
42 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡